NovoCure Q3 revenue +22% to $155M; FDA OKs Optune Lua; CEO/CFO transitions set

NovoCure Ltd

2024-Q3 EPS reported -$0.95 revenue$443,954,000

Q3 net revenues $155.1M (+22% YoY); net loss $30.6M ($0.28 loss per share); adjusted EBITDA $1.7M.
FDA approved Optune Lua for metastatic NSCLC; Breakthrough Device designation for brain metastases from NSCLC.
CEO Asaf Danziger retiring Jan 1, 2025; CFO Ashley Cordova to become CEO on that date.
Christoph Brackmann appointed CFO (from Moderna), effective Jan 1, 2025; compensation disclosed.
Active patients on therapy 4,113; prescriptions up 8% to 1,586; cash and equivalents $959.9M.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christoph Brackmann

Chief Financial Officer

NVCR · NovoCure Ltd

Effective: 2025-01-01
Filed: October 30, 2024, 7:59 PM ET

On October 30, 2024, the Company announced the appointment of Christoph Brackmann, age 51, as the Chief Financial Officer of the Novocure Group, effective January 1, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christoph Brackmann was appointed as Chief Financial Officer at NovoCure Ltd.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On October 30, 2024, the Company announced the appointment of Christoph Brackmann, age 51, as the Chief Financial Officer of the Novocure Group, effective January 1, 2025.

View on SEC.gov

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-24-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.